Skip to main content

Table 4 Factors associated with longitudinal changes in TNFi trough serum levels over 1 year of follow-up using GEE multivariate models

From: Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study

Variable TNFi trough serum levels p value
β coefficient (95% CI)
DAS28-ESR 0.26 (0.068–0.004) 0.001
Reduced dose (yes/no) 0.022 (0.168–0.012) 0.271
Diagnosis (RA/PsA) 0.005 (0.058–0.144) 0.662
Monotherapy (yes/no) 0.0004 (0.090–0.062) 0.863
Follow-up
 Baseline 1  
 4-month visit 0.012 (0.044–0.0004) 0.023
 8-month visit 0.004 (0.032–0.002) 0.280
 12-month visit 0.002 (0.005–0.032) 0.409
Steroids 0.020 (0.325–0.090) 0.538
Constant 4.45 (2.99 to 6.25) < 0.0001
  1. Significant values are shown in bold typeface
  2. CI confidence interval, DAS28-ESR 28-joint Disease Activity Score-erythrocyte sedimentation rate, GEE generalized estimating equation, PsA psoriatic arthritis, RA rheumatoid arthritis, TNFi tumor necrosis factor inhibitors